BR112016007474A2 - diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal - Google Patents

diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal

Info

Publication number
BR112016007474A2
BR112016007474A2 BR112016007474A BR112016007474A BR112016007474A2 BR 112016007474 A2 BR112016007474 A2 BR 112016007474A2 BR 112016007474 A BR112016007474 A BR 112016007474A BR 112016007474 A BR112016007474 A BR 112016007474A BR 112016007474 A2 BR112016007474 A2 BR 112016007474A2
Authority
BR
Brazil
Prior art keywords
treatment
diagnosis
inflammatory bowel
bowel syndrome
irritable bowel
Prior art date
Application number
BR112016007474A
Other languages
English (en)
Inventor
Chang Christopher
Pimentel Mark
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016007474(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of BR112016007474A2 publication Critical patent/BR112016007474A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo da patente de invenã§ã£o para: “diagnã“stico e tratamento de sãndrome do intestino irritãvel e doenã‡a inflamatã“ria intestinal” a presente invenã§ã£o descreve mã©todos, ensaios e sistemas de diagnã³stico, seleã§ã£o e tratamento da sã­ndrome do intestino irritã¡vel (sii) com base no nã­vel de um sujeito de anticorpos anti-vinculina e anti-cdtb. a sii pode ser distinguida da doenã§a inflamatã³ria do intestino (dii), utilizando os mã©todos, ensaios e sistemas aqui descritos.
BR112016007474A 2013-10-09 2014-10-09 diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal BR112016007474A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09
PCT/US2014/059957 WO2015054529A1 (en) 2013-10-09 2014-10-09 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Publications (1)

Publication Number Publication Date
BR112016007474A2 true BR112016007474A2 (pt) 2017-09-12

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007474A BR112016007474A2 (pt) 2013-10-09 2014-10-09 diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal

Country Status (20)

Country Link
US (2) US9851361B2 (pt)
EP (1) EP3054977B1 (pt)
JP (1) JP6567509B2 (pt)
KR (1) KR102259588B1 (pt)
CN (1) CN105744956B (pt)
AU (2) AU2014331841B2 (pt)
BR (1) BR112016007474A2 (pt)
CA (1) CA2923651C (pt)
CL (1) CL2016000820A1 (pt)
ES (1) ES2892905T3 (pt)
HK (1) HK1221898A1 (pt)
IL (1) IL244971B2 (pt)
MX (1) MX2016004167A (pt)
NZ (1) NZ717633A (pt)
PE (1) PE20160882A1 (pt)
PL (1) PL3054977T3 (pt)
PT (1) PT3054977T (pt)
RU (1) RU2683781C2 (pt)
SG (1) SG11201601733VA (pt)
WO (1) WO2015054529A1 (pt)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869676B2 (en) 2009-02-11 2018-01-16 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
CN117286238A (zh) * 2016-05-20 2023-12-26 西达-赛奈医疗中心 基于基因的炎性肠病诊断
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
ATE491953T1 (de) * 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
ES2456710T3 (es) 2003-12-05 2014-04-23 Fuso Pharmaceutical Industries Ltd. Genes de toxinas de distensión citoletales como dianas para la detección de bacterias Campylobacter
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
EP2562544A1 (en) 2007-12-20 2013-02-27 InDex Diagnostics AB kits for use in the differentiation of IBD and IBS and further distinction between disease types of IBD
EP2370435B1 (en) 2008-11-24 2015-01-07 Cedars-Sinai Medical Center Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
MX348670B (es) 2009-02-11 2017-06-23 Cedars Sinai Medical Center Anticuerpo contra toxina de distensión citoletal de campylobacter jejuni.
BRPI1008058A8 (pt) 2009-02-11 2018-03-27 Cedars Sinai Medical Center uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
ES2646598T3 (es) 2012-09-17 2017-12-14 Cedars-Sinai Medical Center Diagnóstico y tratamiento de los trastornos de la motilidad del intestino y la vejiga, y de la fibromialgia
EP3054977B1 (en) 2013-10-09 2021-07-21 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
WO2018140869A1 (en) 2017-01-30 2018-08-02 Cedars-Sinai Medical Center Diagnosis of scleroderma

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869676B2 (en) 2009-02-11 2018-01-16 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10527621B2 (en) 2009-02-11 2020-01-07 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10466254B2 (en) 2012-09-17 2019-11-05 Cedars-Sinai Medical Center Method of measuring a level of anti-vinculin antibodies in a biological sample
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10690679B2 (en) 2014-10-09 2020-06-23 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Also Published As

Publication number Publication date
KR102259588B1 (ko) 2021-06-02
RU2683781C2 (ru) 2019-04-02
IL244971B1 (en) 2023-08-01
US9851361B2 (en) 2017-12-26
MX2016004167A (es) 2016-06-24
US20180196063A1 (en) 2018-07-12
KR20160062161A (ko) 2016-06-01
US20170038393A1 (en) 2017-02-09
AU2014331841A1 (en) 2016-03-24
PT3054977T (pt) 2021-10-14
PL3054977T3 (pl) 2021-12-20
AU2020203468A1 (en) 2020-06-18
HK1221898A1 (zh) 2017-06-16
RU2016116766A (ru) 2017-11-15
US10352944B2 (en) 2019-07-16
EP3054977B1 (en) 2021-07-21
AU2014331841B2 (en) 2020-03-12
WO2015054529A1 (en) 2015-04-16
CN105744956A (zh) 2016-07-06
JP2017502253A (ja) 2017-01-19
IL244971A0 (en) 2016-05-31
CL2016000820A1 (es) 2016-09-23
EP3054977A4 (en) 2017-04-12
NZ717633A (en) 2021-07-30
ES2892905T3 (es) 2022-02-07
PE20160882A1 (es) 2016-09-14
CA2923651C (en) 2023-03-14
CN105744956B (zh) 2021-07-20
EP3054977A1 (en) 2016-08-17
JP6567509B2 (ja) 2019-08-28
IL244971B2 (en) 2023-12-01
CA2923651A1 (en) 2015-04-16
SG11201601733VA (en) 2016-04-28

Similar Documents

Publication Publication Date Title
BR112016007474A2 (pt) diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal
BR112015010012A2 (pt) método; e sistema
BR112015029320A2 (pt) ensaios específicos de vias para predição de diagnóstico de síndrome do intestino irritável
BR112014013082A2 (pt) método para detectar adutos nucleossomos
CL2020002225A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal
CL2014000642A1 (es) Compuestos derivados de indazol-3-carboxamidas, como inhibidores de la ruta de señalizacion de wnt/b-catenina; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, artritis reumatoide, infecciones micoticas y viricas, enfermedad de parkinson, un trastorno fibrotico, entre otras enfermedades.
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112015023706A2 (pt) painel de biomarcadores isolados, método de determinação de probabilidade de parto prematuro, método de prever gab, método para prever o tempo de parto e método de determinação da probabilidade para o parto normal.
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
BR112017004899A2 (pt) detecção de proteínas mal dobradas
EA201490533A1 (ru) Способы и композиции для определения статуса в отношении курения
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112014009223A2 (pt) método para o diagnóstico da doença de niemann-pick
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
DK3578635T3 (da) Immunoassay, som anvender indfangningskonjugat
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
BR112015012483A2 (pt) capô de turbomáquina com a capacidade de recobrir um cone de soprador
BR112017027304A2 (pt) método para o diagnóstico de doença de farber
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
BR112016003030A2 (pt) anticorpos iib do receptor anti-fc-gama e uso dos mesmos
AR105542A1 (es) USO DE LOS MARCADORES MOLECULARES IL-3, IL-33 E IL-12p40 PARA CARACTERIZAR LA SEVERIDAD DE INFECCIONES RESPIRATORIAS POR VIRUS RESPIRATORIO SINCICIAL Y METAPNEUMOVIRUS HUMANO

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]